Treating method for circular RNA in systemic lupus erythematosus

Abstract

Provided is a treating method for circular RNA in systemic lupus erythematosus. The treating method comprises the following steps that a systemic lupus erythematosus group, a rheumatoid arthritis group and a normal control group are set, each group comprises a plurality of parts of whole blood samples which are detached from the human body of different human bodies, , peripheral blood mononuclear cells are obtained by separating correspondingly; total RNA in all peripheral blood mononuclear cells is extracted correspondingly; ribonucleic acid labeling and chip hybridization are conducted; and the fluorescence intensity of a chip after hybridization is scanned, the obtained chip scanning result is analyzed, and circular RNA differently expressed between the systemic lupus erythematosus group and the normal control group as well as the systemic lupus erythematosus group and the rheumatoid arthritis group is sieved. According to the treating method for the circular RNA in the systemic lupus erythematosus, circ RNA abnormally expressed by the systemic lupus erythematosus is obtained and can serve as a potential diagnostic marker for the systemic lupus erythematosus, and sufficient theoretical basis for studying pathogenesis of the systemic lupus erythematosus can be further provided.

Description

technical field [0001] The invention relates to an acquisition of systemic lupus erythematosus gene information as an intermediate result, in particular to a method for processing circular RNA of systemic lupus erythematosus. Background technique [0002] Systemic lupus erythematosus (SLE) is a typical autoimmune-mediated diffuse connective tissue disease characterized by immune inflammation. A variety of autoantibodies represented by antinuclear antibodies in serum and multi-organ involvement are the two main clinical features. The clinical manifestations of the disease are complicated, the course of the disease is protracted and repeated, exacerbation and remission alternately, and it has obvious gender tendency. 80-90% of the patients are women, and women of childbearing age between 20 and 40 years old are more common. SLE patients are increasing all over the world. In my country, the prevalence of SLE is about 1 / 1000, and the total number of patients is as high as 1 mil...

AI Technical Summary

Problems solved by technology

[0003] At present, the necessary condition for the diagnosis of SLE is anti-nuclear antibody, but the results of anti-nuclear antibody test in different laboratories may be different

In addition, although anti-double-stranded DNA (ds-DNA) has strong specificity for diagnosing lupus, depending on the test method, anti-ds-DNA is not necessarily highly sensitive and sometimes unpredictable disease activity

Some scholars believe that indicators such as autoantibody formation or complement activation cannot actually predict the severity and prognosis of SLE.

Thus, there is still no proven and widely accepted biomarker for SLE

Images